Corify Care

About Corify Care

Corify Care is a Spanish medical technology company founded in 2019 as a spin-off from the Hospital General Universitario Gregorio Marañón in Madrid and the Universitat Politècnica de València. The company was co-founded by CEO Andreu Climent, CSO María Guillem, and CMO Felipe Atienza. Andreu Climent, a telecommunications engineer, began the research that would lead to Corify Care in 2005 and later developed the core technology between 2015 and 2016 while at the Gregorio Marañón Hospital.

The firm develops solutions to improve the clinical management of cardiac arrhythmias. Its core product is the ACORYS® MAPPING SYSTEM, a non-invasive cardiac mapping technology that creates detailed 3D electroanatomical maps of the heart's electrical activity in under 10 minutes. This system utilizes 128 sensors on the patient's torso and a 3D model, eliminating the need for CT or MRI scans and allowing clinicians to see the heart's activity in real-time. The primary goal is to enhance the diagnosis, treatment planning, and guidance for procedures targeting arrhythmias like atrial fibrillation and ventricular tachycardia. By providing a detailed map before and during an intervention, ACORYS aims to make procedures faster, more precise, and safer.

Corify Care's business model is centered on selling its ACORYS® system to hospitals and cardiac care centers. After achieving the CE Mark under the new Medical Device Regulation (MDR) in July 2024, the system is approved for commercial sale across the European Union. The company is actively working on European expansion and is also pursuing FDA approval to enter the U.S. market. The company serves electrophysiologists and cardiologists, providing them with a tool to improve success rates for cardiac ablations and pacemaker implantations. The company is also developing ACORYS 2.0, which will integrate digital twins and artificial intelligence for more personalized treatment.

Since its inception, Corify Care has secured significant funding from various sources. It has received support from EIT Health, including over €2.5 million for a clinical trial involving more than 1,000 patients. In 2020, its technology was named the most innovative in Europe by EIT Health. By late 2024, the company announced it had secured a total of €6 million, combining a €3 million funding round led by Clave-Mondragón with an additional €3 million in public grants to fuel its European and U.S. expansion.